tldrdailynews.com logo
Tag

Pharma

All articles tagged with #pharma

Merck Secures Global Rights to SciBrunch’s KRAS G12D Inhibitor in $2.13B Deal
pharma22 days ago

Merck Secures Global Rights to SciBrunch’s KRAS G12D Inhibitor in $2.13B Deal

Merck & Co. has acquired worldwide rights to SPR2015, a preclinical KRAS G12D inhibitor from Shanghai-based biotech SciBrunch, for an upfront payment of $400 million and potential total value of $2.13 billion. The deal, which closed in September 2026, positions Merck to expand its oncology pipeline beyond its existing KRAS G12C inhibitor, calderasib, while SciBrunch secures its first major partnership. SPR2015 is designed to target a prevalent mutation found in approximately 38% of pancreatic cancer patients and is expected to enter human trials by the end of 2026.

via Endpoints News|
#drug-licensing#kras-g12d#merck
Novo Nordisk CEO signals M&A interest after investor backlash to turnaround plan
business28 days ago

Novo Nordisk CEO signals M&A interest after investor backlash to turnaround plan

Novo Nordisk CEO Mike Doustdar indicated the company is exploring mergers and acquisitions to address gaps in its pipeline, following a sharp stock drop after its Capital Markets Day. The company aims to launch five 'multi-blockbuster' drugs by 2030 and diversify into areas like blood and endocrine disorders. Investors remain skeptical of the growth strategy, which analysts view as merely matching industry peers rather than outperforming them.

via cnbc.com|
#business#eli-lilly#glp-1
Novartis Halts ALS Drug VHB937 After Phase 2 Trial Misses All Endpoints
pharma1 month ago

Novartis Halts ALS Drug VHB937 After Phase 2 Trial Misses All Endpoints

Novartis has discontinued development of VHB937, an experimental drug for amyotrophic lateral sclerosis (ALS), after its Phase 2 trial failed to meet primary and secondary endpoints. The trial, known as Astrals, involved 251 patients with early-stage ALS and compared the TREM2 stabilizer against a placebo. This setback extends a recent string of R&D failures for the Swiss pharmaceutical giant, including missed targets in cardiovascular and muscle-wasting disease trials. While the ALS program is scrapped, Novartis is continuing Phase 2 testing of the same compound for Alzheimer’s disease, where the target mechanism is considered more robust. The failure adds to a broader trend of unsuccessful clinical trials for TREM2-based therapies across the industry.

via Endpoints News|
#als#novartis#pharma
Sentivera Secures $1.5B Deal for Haisco’s Type 2 Inflammation Candidate
biotech1 month ago

Sentivera Secures $1.5B Deal for Haisco’s Type 2 Inflammation Candidate

ARCH Venture Partners and Population Health Partners have launched a new biotech, Sentivera, to acquire global rights to a preclinical drug candidate from China’s Haisco Pharmaceutical. The deal is valued at up to $1.5 billion, with Haisco receiving $75.9 million upfront and equity for a 17.5% stake. The candidate targets Type 2 inflammatory diseases and has recently received clinical trial approval in China.

via Fierce Biotech|
#biotech#china#immunology
AstraZeneca and Bristol Myers Squibb reportedly eye record $400B merger
business2 months ago

AstraZeneca and Bristol Myers Squibb reportedly eye record $400B merger

UK drugmaker AstraZeneca and US rival Bristol Myers Squibb are reportedly weighing a merger valued at about $400 billion, potentially the largest deal in history. Talks have been ongoing for months with no commitment or comment from either side, and the deal would reshape both companies’ cancer-drug portfolios and strategic positioning in the pharma industry.

via CNBC|
#astrazeneca#bristol-myers-squibb#business
Cold-Chain Shipping Roars as UPS, FedEx and Peers Tap the Healthcare Boom
business2 months ago

Cold-Chain Shipping Roars as UPS, FedEx and Peers Tap the Healthcare Boom

Logistics giants like UPS, FedEx, DHL and others are expanding temperature-controlled capabilities to service a booming healthcare market driven by GLP-1 therapies (e.g., Ozempic/Wegovy, Mounjaro/Zepbound) and other biologics, investing in refrigerated facilities and AI-enabled tracking to ensure end-to-end cold-chain reliability. Demand is projected to grow about 8.3% CAGR to 2033, reaching roughly $39 billion, as companies report rising healthcare revenues and shift toward specialized therapies and patient-focused delivery.

via CNBC|
#business#cold-chain#glp-1
GSK pivots to oncology expansion with $10.6B Nuvalent takeover
business4 months ago

GSK pivots to oncology expansion with $10.6B Nuvalent takeover

GSK agreed to acquire Nuvalent for $10.6 billion in cash, paying about $124 per share (roughly a 40% premium) to bolster its oncology pipeline and offset expected HIV revenue declines when its best-selling HIV medicine loses exclusivity in 2028. Nuvalent brings late-stage lung-cancer assets neladalkib and zidesamtinib, plus an early-stage and preclinical portfolio, with potential blockbusters if approved by the FDA. The deal would be GSK’s second-largest ever and signals a shift toward larger biotech deals amid strong M&A activity, with guidance unchanged for 2026 and growth anticipated from 2027.

via CNBC|
#biotech#business#lung-cancer
BMS inks $15B China-backed deal to fast-track Hengrui assets
business5 months ago

BMS inks $15B China-backed deal to fast-track Hengrui assets

Bristol Myers Squibb is striking a broad deal with Hengrui Pharma worth up to $15.2 billion, featuring $600 million upfront for 13 early-stage programs, ex-China rights to four oncology/hematology assets, and joint discovery on five candidates; Hengrui will gain access to BMS immunology assets in China, Hong Kong and Macau and lead early development to proof of concept, in a move that leverages China's reportedly faster timelines (50–70% quicker) to clinical proof of concept.

via Fierce Biotech|
#biotech#bms#business